Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Notes Payables: 2018-2025

  • Dr Reddys Laboratories' Notes Payables rose 190.85% to $445.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $445.0 million, marking a year-over-year increase of 190.85%. This contributed to the annual value of $445.0 million for FY2025, which is 190.85% up from last year.
  • Latest data reveals that Dr Reddys Laboratories reported Notes Payables of $445.0 million as of Q1 2025, which was up 190.85% from $153.0 million recorded in Q1 2024.
  • Dr Reddys Laboratories' Notes Payables' 5-year high stood at $445.0 million during Q1 2025, with a 5-year trough of $90.0 million in Q1 2023.
  • Its 3-year average for Notes Payables is $229.3 million, with a median of $153.0 million in 2024.
  • Its Notes Payables has fluctuated over the past 5 years, first slumped by 74.79% in 2023, then spiked by 190.85% in 2025.
  • Dr Reddys Laboratories' Notes Payables (Quarterly) stood at $316.0 million in 2021, then increased by 12.97% to $357.0 million in 2022, then tumbled by 74.79% to $90.0 million in 2023, then spiked by 70.00% to $153.0 million in 2024, then soared by 190.85% to $445.0 million in 2025.
  • Its Notes Payables was $445.0 million in Q1 2025, compared to $153.0 million in Q1 2024 and $90.0 million in Q1 2023.